Zacks Investment Research lowered shares of Kadmon (NYSE:KDMN) from a buy rating to a hold rating in a research note published on Tuesday morning.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
A number of other equities analysts have also recently issued reports on the stock. HC Wainwright restated a buy rating and issued a $25.00 price objective on shares of Kadmon in a research report on Friday, December 15th. WBB Securities lowered shares of Kadmon from a hold rating to a sell rating and set a $3.00 target price on the stock. in a research note on Monday, October 9th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Kadmon presently has a consensus rating of Hold and an average price target of $8.65.
Kadmon (NYSE:KDMN) opened at $4.88 on Tuesday. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.00. The stock has a market cap of $357.04, a PE ratio of -2.79 and a beta of 2.54.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The business had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. During the same quarter last year, the firm earned ($4.24) EPS. The company’s revenue for the quarter was down 60.0% on a year-over-year basis. analysts forecast that Kadmon will post -1.61 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its stake in shares of Kadmon by 3,211.2% during the 3rd quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after purchasing an additional 429,752 shares in the last quarter. Crestline Management LP bought a new stake in shares of Kadmon during the 3rd quarter valued at about $2,011,000. Old West Investment Management LLC bought a new stake in shares of Kadmon during the 3rd quarter valued at about $169,000. Wells Fargo & Company MN boosted its stake in shares of Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after purchasing an additional 13,923 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Kadmon during the 3rd quarter valued at about $3,685,000. 51.90% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Kadmon (KDMN) Rating Lowered to Hold at Zacks Investment Research” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/01/20/kadmon-kdmn-rating-lowered-to-hold-at-zacks-investment-research.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.